ELAHERE 100 mg/20 ml, concentrate for solution for infusion

( ARTG ) ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens (see Section 4.2).